Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Source: SeekingAlpha
2026-03-10 14:08:54 ET
The last time I spoke about Dianthus Therapeutics, Inc. ( DNTH ), it was in a Seeking Alpha article entitled " Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition ." With respect to this article, I mentioned that the company was in the process of developing claseprubart [known as DNTH103 at that time] for the treatment of patients with Myasthenia Gravis [MG] in the ongoing phase 2 MaGic trial. I had a Buy rating at that time, and the stock has gained 174.53% since then....
Read the full article on Seeking Alpha
For further details see:
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Sanofi
NASDAQ: SNY
SNY Trading
-0.56% G/L:
$44.155 Last:
1,077,036 Volume:
$44.07 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
